Gabriel Sciences, LLC

Gabriel Sciences is a biotech company with the mission to advance the treatment and understanding of mental illness through its translational research, including collaborative opportunities with academic medicine. Founder David Pickar MD is former Chief of the Experimental Therapeutics Branch at National Institute of Mental Health (NIMH) and currently holds adjunct appointments as Professor of Psychiatry at Johns Hopkins University School of Medicine and the Uniformed Services University of the Health Sciences. Gabriel Sciences has been the recipient of NIH SBIR Phase I and Phase II grants for the development of a clinical DNA database enabling predictors of antipsychotic drug response. Current focus is on the use of alpha 2 noradrenergic receptor antagonist drugs.

Drug Development

As Chief of the Experimental Therapeutics Branch, Intramural Research Program, National Institute of Mental Health, Dr. Pickar contributed leadership to the emerging field of translational genetics. Dr. Pickar’s invention at the NIH for treatment of schizophrenia is currently in FDA stage IIb of clinical development. Since retirement from the NIH and the United States Public Health Service, Dr. Pickar has founded three companies related to drug development for CNS disorders and serves on the Psychiatry Advisory Board of the Food and Drug Administration.

Dr. Pickar’s experience with biotech companies in the CNS arena coupled with his research and academic experience provide a unique perspective and knowledge base. He offers specific consultation in:

  • Scientific rationale and support
  • Clinical design and implementation
  • Clinical utilization as it relates to market assessment